Clinical Trial Update: Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial comparing methotrexate to secukinumab safety in psoriasis patients with metabolic syndrome; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Psoriasis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Secukinumab (secukinumab)

Snippet

Sponsor: Universita di Verona | Conditions: Psoriasis, Metabolic Syndrome | Phase 4 | Status: UNKNOWN